CHICAGO / Dec 18, 2023 / Business Wire / GE HealthCare (Nasdaq: GEHC) is announcing today that President and Chief Executive Officer, Peter Arduini, and Vice President and Chief Financial Officer, Jay Saccaro, will attend the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9th in San Francisco. Both GE HealthCare executives will participate in a Q&A session following Arduini’s presentation at 2:15 pm ET/11:15 am PT.
This live webcast can be accessed by visiting GE HealthCare’s Investor Relations website here https://investor.gehealthcare.com/news-events/events, where it will also be archived.
About GE HealthCare Technologies Inc.
GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 100 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are an $18.3 billion business with 50,000 employees working to create a world where healthcare has no limits.
Follow us on LinkedIn, Twitter, and Insights for the latest news, or visit our website gehealthcare.com for more information.
| Last Trade: | US$77.09 |
| Daily Change: | -2.16 -2.73 |
| Daily Volume: | 3,055,620 |
| Market Cap: | US$35.220B |
December 05, 2024 December 03, 2024 December 01, 2024 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
